- Trial Phase
- Approved (CE-marked in Europe)
- Time to Market
- Already CE-marked and commercializing in Europe. US market entry via the PRIME study with Labcorp is in progress with no announced timeline.
- Why 3/10
- There is no upcoming PDUFA date, pivotal readout, or other hard binary catalyst for Proclarix in the next ~12 months. The drug is already CE-marked and commercializing in Europe; the PRIME study with Labcorp is ongoing but has no announced readout date. The company is pivoting to AI robotics, making Proclarix a legacy asset. ImpactScore is low because the stock is driven by dilution and the Realbotix acquisition, not by this diagnostic.
Proclarix is a minor legacy asset at a company in severe financial distress that is pivoting to AI robotics. ONCO stock is driven by dilution risk and the Realbotix acquisition, not by Proclarix's commercial progress. Investors should monitor the pending Realbotix deal closing timeline and the massive share overhang from the Seven Knots S-1 registration, not Proclarix-specific catalysts.
Price Chart
Executive Summary
Proclarix is a CE-marked blood-based diagnostic test for prostate cancer being commercialized in Europe by Onconetix, Inc. (ONCO), a micro-cap biotech company in severe financial distress. The company has a going concern warning, ~$5.1M in cash, a ~$3M market cap, and is pivoting to AI/humanoid robotics via a pending all-stock acquisition of Realbotix LLC. Proclarix is a legacy asset with no near-term binary catalyst — the PRIME study with Labcorp for US market entry is ongoing but has no announced readout date. The stock is primarily driven by extreme dilution risk (an S-1 effective for up to 100M shares of resale, representing ~2,282% of outstanding) and the Realbotix deal timeline, not by Proclarix's commercial progress.
How It Works
Proclarix is a blood-based diagnostic test for prostate cancer. It analyzes specific protein biomarkers in a blood sample to help doctors assess a patient's risk of having clinically significant prostate cancer, potentially reducing the number of unnecessary prostate biopsies. It is designed to be used alongside PSA testing and MRI to improve diagnostic accuracy.
Trial Status
Proclarix is CE-marked and commercially available in Europe. The PRIME study with Labcorp was initiated in Q1 2026 for US clinical validation. New clinical publications supporting the test were highlighted in the Q1 2026 operational update.
The Two-Sided Case
Upcoming Catalysts
- PRIME study with Labcorp progress/readout (no announced date)
- Realbotix acquisition closing (expected H2 2026) — this is the primary stock driver, not Proclarix
- Potential further dilutive financings given going concern and minimal cash
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Onconetix, Inc. S-1 ONCO ·Originating report